Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (161-170 of 311) with videos related to

Pageof 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 25, 2017
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibitionAhmad Najem, Mohammad Krayem, François Salès, et al.
Archives of Gynecology and Obstetrics|February 15, 2008
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinomaDaniela D Rosa, Ahmad Awada, Max S Mano, et al.
Melanoma Research|July 8, 2009
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patientsPierre Vereecken, Ahmad Awada, Stefan Suciu, et al.
Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie|February 22, 2023
Incidental finding of solitary fibrous tumor of male breast: case report and review of literatureEtienne El-Helou, Manar Zaiter, Huu Hoang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 31, 2007
A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgeryPierre Vereecken, Ahmad Awada, Ghanem Ghanem, et al.
Expert Opinion on Biological Therapy|May 27, 2021
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeuticsKamal S Saini, Kevin Punie, Chris Twelves, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursPatrick Schöffski, Ahmad Awada, Herlinde Dumez, et al.
Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.
Molecular Cancer Research : MCR|March 20, 2021
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-KitMalak Sabbah, Mohammad Krayem, Ahmad Najem, et al.
Ecancermedicalscience|December 21, 2016
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisationLinda Cairns, Sandrine Aspeslagh, Andrea Anichini, et al.
Pageof 32

Showing results (161-170 of 311) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|July 25, 2017
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibitionAhmad Najem, Mohammad Krayem, François Salès, et al.
Archives of Gynecology and Obstetrics|February 15, 2008
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinomaDaniela D Rosa, Ahmad Awada, Max S Mano, et al.
Melanoma Research|July 8, 2009
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patientsPierre Vereecken, Ahmad Awada, Stefan Suciu, et al.
Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie|February 22, 2023
Incidental finding of solitary fibrous tumor of male breast: case report and review of literatureEtienne El-Helou, Manar Zaiter, Huu Hoang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 31, 2007
A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgeryPierre Vereecken, Ahmad Awada, Ghanem Ghanem, et al.
Expert Opinion on Biological Therapy|May 27, 2021
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeuticsKamal S Saini, Kevin Punie, Chris Twelves, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursPatrick Schöffski, Ahmad Awada, Herlinde Dumez, et al.
Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.
Molecular Cancer Research : MCR|March 20, 2021
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-KitMalak Sabbah, Mohammad Krayem, Ahmad Najem, et al.
Ecancermedicalscience|December 21, 2016
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisationLinda Cairns, Sandrine Aspeslagh, Andrea Anichini, et al.
Pageof 32